跳至主要内容
临床试验/DRKS00009945
DRKS00009945
已完成
不适用

Observational study to collect data on treatment progression in women treated for bladder weakness (overactive bladder with or without incontinence) with GRANU FINK® femina - DCH/017714

Omega Pharma Innovation & Development NV0 个研究点目标入组 123 人2016年3月9日

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
bladder weakness (overactive bladder with or without incontinence)
发起方
Omega Pharma Innovation & Development NV
入组人数
123
状态
已完成
最后更新
去年

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2016年3月9日
结束日期
2017年2月23日
最后更新
去年
研究类型
Observational
性别
Female

研究者

发起方
Omega Pharma Innovation & Development NV

入排标准

入选标准

  • Recommended therapy with GRANU FINK® femina
  • Age 18\-78 years
  • BMI 18\.5 \- 29\.9 kg/m2
  • No existing pregnancy in women of childbearing potential (premenopausal women without surgical sterilization)
  • Women of child\-bearing potential: currently uses reliable method of contraception
  • Willing and able to comply with diary and questionnaire completion
  • Written consent of the patient

排除标准

  • Known hypersensitivity to one of the product ingredients (e.g. hop, sumach bark, pumpkin seeds) or pumpkin\-related plants as water melon, zucchini; soya, and peanut
  • Women only suffer on stress incontinence
  • Chronic or current cystitis
  • Untreated or non\-stabilized diabetes (type I or II) or diagnosed within the last 6 months prior to study selection
  • Incontinence surgeries (e.g. colposuspension, sling placement)
  • Neurologic disease (e.g. multiple sclerosis, Parkinson’s disease, symptomatic herniated disc etc.)
  • Women of childbearing potential: pregnancy (current or within last 12 months) or breast\-feeding
  • Descensus of bladder, uterus, and/or vagina
  • History of malignancy within 5 years prior to start of observation
  • Untreated or non\-stabilised thyroid disorder

结局指标

主要结局

未指定

相似试验